破伤风类毒素、降低抗原含量的白喉毒素和无细胞百日咳联合疫苗的临床研究及其应用进展

Progress in clinical study and application of tetanus toxoid,reduced diphtheria toxoid and acellular pertussis combined vaccine

百白破联合疫苗的应用对预防百日咳、白喉、破伤风起到非常重要的作用。但自上个世纪80年代开始,世界各地普遍出现'百日咳重现'现象,百日咳发病率逐年升高,而成年人感染百日咳并传染婴幼儿成为重要的传播方式。WHO建议成年人接种破伤风类毒素、降低抗原含量的白喉毒素和无细胞百日咳联合疫苗(tetanus toxoid,reduced diphtheria toxoid,and acellular pertussis,Tdap)以预防百日咳。本文对部分Tdap的临床研究及其应用情况作一综述。

The application of diphtheria,tetanus and pertussis(DTP)combined vaccine plays an important role in prevention of the three diseases.However,since 1980 s,pertussis re-emerge has appeared worldwide.The morbidity of pertussis increases year by year,while the infection from adults to infants has become a prominent transmission mode.WHO recommends the vaccination of tetanus toxoid,reduced diphtheria toxoid and acellular pertussis combined vaccine(Tdap)to prevent pertussis.This paper reviews the clinical study and application of partial Tdap.